A Single Arm Phase II Study Osimertinib in Patients with Stage 4 Non-small Cell Lung Cancer with Uncommon EGFR Mutations Thoracic Oncology Program (TOP) Protocol Number: TOP 1703

Administered By

Awarded By

Contributors

Start/End

  • April 30, 2018 - April 30, 2023